Skip to main content

U.S. Department of Health and Human Services HHS.gov

Agency for Healthcare Research and Quality: Advancing Excellence in Health Care AHRQ.gov

1-4 of 4 results for

“Ambulatory Procedure/Imaging Center”

Sort by Relevance | Date
Show 20 | 50 | 100
Learn More About the Compare Feature

Filters

Measure Summary
NQMC:011054
2017 Jun
NQF-Endorsed Measure

Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer.

American Medical Association; American Urological Association

Compare

Measure Summary
NQMC:010099
2014 Nov

Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score prior to initiation of treatment.

American Urological Association; Physician Consortium for Performance Improvement®

Compare

Measure Summary
NQMC:010102
2014 Nov
NQF-Endorsed Measure

Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence, receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist).

American Urological Association; Physician Consortium for Performance Improvement®

Compare

Measure Summary
NQMC:010101
2014 Nov

Prostate cancer: percentage of patients, regardless of age, with a diagnosis of clinically localized prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who received counseling on, at a minimum, the following treatment options for clinically localized disease prior to initiation of treatment: active surveillance, AND interstitial prostate brachytherapy, AND external beam radiotherapy, AND radical prostatectomy.

American Urological Association; Physician Consortium for Performance Improvement®

Compare